Table 1.
Anthropometric and clinical characteristics in TA patients with PH at baseline.
| Variables | TA with PH (n = 32) |
|---|---|
| Clinical characteristics | |
| Age, years | 42.8 ± 11.9 |
| Disease duration at the first procedure, months | 48 (36, 108) |
| Follow up, months | 49.5 (41, 62) |
| Female, n (%) | 28 (87.5%) |
| WHO FC I-II | 15 (46.9%) |
| WHO FC III-IV | 17 (53.1%) |
| Comorbidities, n (%) | |
| Secondary hypertension | 4 (12.5%) |
| Dyslipidemia | 1 (3.1%) |
| Diabetes mellitus | 0 (0.0%) |
| CAD | 0 (0.0%) |
| PAD | 6 (18.8%) |
| Smoking | 0 (0.0%) |
| Medications, n (%) | |
| Prednisone | 24 (75.0%) |
| Immunosuppressants | 3 (9.4%) |
| PH-targeted agents | 30 (93.8%) |
| PDE5 inhibitors | 23 (71.9%) |
| ERA | 21 (65.6%) |
| Prostacyclin Analogue | 7 (21.9%) |
Data are presented as the means ± SD, Median or as numbers and percentages; TA, Takayasu’s arteritis; CAD, coronary artery disease; PAD, peripheral arterial disease; PDE5, phosphodiesterase 5; ERA, endothelin receptor antagonist; PH, pulmonary hypertension.